Cancer - VTX-2337
VTX-2337 is a small molecule Toll-like receptor 8 (TLR8) agonist that stimulates myeloid dendritic cells (mDc), monocytes, and enhances natural killer (NK) cell responses. It is administered subcutaneously (SC) on a weekly basis.
VentiRx has advanced VTX-2337 into a broad clinical development program designed to evaluate the compound in multiple oncology indications in combination with a variety of anticancer agents, including chemotherapy and monoclonal antibody therapy. These include a combination study with doxorubicin in late stage ovarian cancer and a combination trial with cetuximab in head and neck cancer patients. A study of VTX-2337 in pancreatic cancer will be initiated in Q1 2013.